Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX) was the recipient of a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 580,600 shares, a decline of 19.2% from the November 15th total of 718,700 shares. Currently, 2.3% of the shares of the stock are sold short. Based on an average trading volume of 324,300 shares, the short-interest ratio is currently 1.8 days.

Institutional Investors Weigh In On Gain Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Warberg Asset Management LLC acquired a new stake in Gain Therapeutics during the second quarter worth $66,000. Renaissance Technologies LLC grew its holdings in shares of Gain Therapeutics by 154.2% during the 2nd quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after purchasing an additional 72,000 shares during the period. Geode Capital Management LLC grew its holdings in shares of Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after purchasing an additional 88,236 shares during the period. Finally, Hohimer Wealth Management LLC acquired a new stake in shares of Gain Therapeutics during the 2nd quarter worth about $422,000. 11.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GANX has been the subject of a number of research reports. Roth Mkm assumed coverage on shares of Gain Therapeutics in a report on Friday, December 6th. They set a “buy” rating and a $7.00 target price for the company. Roth Capital raised shares of Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Monday, November 25th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Gain Therapeutics currently has an average rating of “Buy” and a consensus price target of $7.25.

Gain Therapeutics Trading Down 2.4 %

Shares of NASDAQ GANX traded down $0.04 during trading on Friday, hitting $1.63. 182,222 shares of the company were exchanged, compared to its average volume of 265,330. The company has a fifty day moving average price of $2.09 and a 200-day moving average price of $1.65. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The firm has a market capitalization of $43.24 million, a PE ratio of -1.48 and a beta of 0.21. Gain Therapeutics has a 12-month low of $0.89 and a 12-month high of $5.33.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.